|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reungwetwattana T, Weroha SJ and Molina
JR: Oncogenic pathways, molecularly targeted therapies and
highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar
|
|
4
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hayama M, Chida M, Karube Y, et al:
One-step nucleic acid amplification for detection of lymph node
metastasis in lung cancer. Ann Thorac Cardiovasc Surg. 20:181–184.
2014. View Article : Google Scholar
|
|
6
|
Coleman RE: Clinical features of
metastatic bone disease and risk of skeletal morbidity. Clin Cancer
Res. 12:6243–6249. 2006. View Article : Google Scholar
|
|
7
|
Sun DS, Hu LK, Cai Y, et al: A systematic
review of risk factors for brain metastases and value of
prophylactic cranial irradiation in non-small cell lung cancer.
Asian Pac J Cancer Prev. 15:1233–1239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Seals DF and Courtneidge SA: The ADAMs
family of metalloproteases: multidomain proteins with multiple
functions. Genes Dev. 17:7–30. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Roy M, Luo YH, Ye M and Liu J: Nonsmall
cell lung cancer therapy: insight into multitargeted small-molecule
growth factor receptor inhibitors. Biomed Res Int. 2013:9647432013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Becherer JD and Blobel CP: Biochemical
properties and functions of membrane-anchored
metalloprotease-disintegrin proteins (ADAMs). Curr Top Dev Biol.
54:101–123. 2003.PubMed/NCBI
|
|
12
|
Duffy MJ, McKiernan E, O’Donovan N and
McGowan PM: Role of ADAMs in cancer formation and progression. Clin
Cancer Res. 15:1140–1144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Peduto L: ADAM9 as a potential target
molecule in cancer. Curr Pharm Des. 15:2282–2287. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
O’Shea C, McKie N, Buggy Y, Duggan C, Hill
AD, McDermott E, O’Higgins N and Duffy MJ: Expression of ADAM-9
mRNA and protein in human breast cancer. Int J Cancer. 105:754–761.
2003. View Article : Google Scholar
|
|
15
|
Tannapfel A, Anhalt K, Häusermann P,
Sommerer F, Benicke M, Uhlmann D, Witzigmann H, Hauss J and
Wittekind C: Identification of novel proteins associated with
hepatocellular carcinomas using protein microarrays. J Pathol.
201:238–249. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Carl-McGrath S, Lendeckel U, Ebert M,
Roessner A and Röcken C: The disintegrin-metalloproteinases ADAM9,
ADAM12 and ADAM15 are upregulated in gastric cancer. Int J Oncol.
26:17–24. 2005.
|
|
17
|
Grützmann R, Lüttges J, Sipos B, Ammerpohl
O, Dobrowolski F, Alldinger I, Kersting S, Ockert D, Koch R,
Kalthoff H, Schackert HK, Saeger HD, et al: ADAM9 expression in
pancreatic cancer is associated with tumour type and is a
prognostic factor in ductal adenocarcinoma. Br J Cancer.
90:1053–1058. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fritzsche FR, Jung M, Tölle A, Wild P,
Hartmann A, Wassermann K, Rabien A, Lein M, Dietel M, Pilarsky C,
Calvano D, Grützmann R, et al: ADAM9 expression is a significant
and independent prognostic marker of PSA relapse in prostate
cancer. Eur Urol. 54:1097–1106. 2008. View Article : Google Scholar
|
|
19
|
Fritzsche FR, Wassermann K, Jung M, Tölle
A, Kristiansen I, Lein M, Johannsen M, Dietel M, Jung K and
Kristiansen G: ADAM9 is highly expressed in renal cell cancer and
is associated with tumour progression. BMC Cancer. 8:1792008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zubel A, Flechtenmacher C, Edler L and
Alonso A: Expression of ADAM9 in CIN3 lesions and squamous cell
carcinomas of the cervix. Gynecol Oncol. 114:332–336. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang J, Qi J, Chen N, Fu W, Zhou B and He
A: High expression of a disintegrin and metalloproteinase-9
predicts a shortened survival time in completely resected stage I
non-small cell lung cancer. Oncol Lett. 5:1461–1466.
2013.PubMed/NCBI
|
|
22
|
Shintani Y, Higashiyama S, Ohta M,
Hirabayashi H, Yamamoto S, Yoshimasu T, Matsuda H and Matsuura N:
Overexpression of ADAM9 in non-small cell lung cancer correlates
with brain metastasis. Cancer Res. 64:4190–4196. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu Q, Liu X, Cai Y, Yu Y and Chen W:
RNAi-mediated ADAM9 gene silencing inhibits metastasis of adenoid
cystic carcinoma cells. Tumour Biol. 31:217–224. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Micocci KC, Martin AC, Montenegro Cde F,
et al: ADAM9 silencing inhibits breast tumor cell invasion in
vitro. Biochimie. 95:1371–1378. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin Y, Peng S and Yu H: RNAi-mediated
downregulation of NOB1 suppresses the growth and colony-formation
ability of human ovarian cancer cells. Med Oncol. 29:311–317. 2012.
View Article : Google Scholar
|
|
26
|
Klein T and Bischoff R: Active
metalloproteases of the A Disintegrin and Metalloprotease (ADAM)
family: biological function and structure. J Proteome Res.
10:17–33. 2011. View Article : Google Scholar
|
|
27
|
Murphy G: The ADAMs: signalling scissors
in the tumour microenvironment. Nat Rev Cancer. 8:929–941. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rocks N, Paulissen G, El Hour M, et al:
Emerging roles of ADAM and ADAMTS metalloproteinases in cancer.
Biochimie. 90:369–379. 2008. View Article : Google Scholar
|
|
29
|
Peduto L, Reuter VE, Shaffer DR, Scher HI
and Blobel CP: Critical function for ADAM9 in mouse prostate
cancer. Cancer Res. 65:9312–9319. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu CM, Hsieh CL, He YC, et al: In vivo
targeting of ADAM9 gene expression using lentivirus-delivered shRNA
suppresses prostate cancer growth by regulating REG4 dependent cell
cycle progression. PLoS One. 8:e537952013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hamada S, Satoh K, Fujibuchi W, et al:
MiR-126 acts as a tumor suppressor in pancreatic cancer cells via
the regulation of ADAM9. Mol Cancer Res. 10:3–10. 2012. View Article : Google Scholar
|
|
32
|
Zhang J and Hua ZC: Targeted gene
silencing by small interfering RNA-based knock-down technology.
Curr Pharm Biotechnol. 5:1–7. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Uprichard SL: The therapeutic potential of
RNA interference. FEBS Lett. 579:5996–6007. 2005. View Article : Google Scholar : PubMed/NCBI
|
